Hepatitis B&C Training Program and Treatment Update 2018 - San Diego
In-Person Event
Jul 28, 2018
San Diego, California, USASpeakers
OVERVIEW
Hepatitis B&C Training Program and Treatment Update 2018 is organized by Scripps Health and will be held on Jul 28, 2018 at San Diego Marriott La Jolla, San Diego, California, United States of America. This CME Conference has been approved for a maximum of 7.00 AMA PRA Category 1 Credits.
Conference Description:
This Update will contribute towards increasing the number of healthcare practitioners educated on the prevalence of chronic viral hepatitis, as well as those properly preventing, diagnosing, treating, and/or referring patients with chronic illness; therefore contributing towards prevention of new cases and improved management of already infected patients.
Viral hepatitis is the seventh leading cause of death in the world, killing more people than traffic injuries, HIV and AIDS, or diabetes. Every year chronic viral hepatitis, of which hepatitis B and C are the most common forms, kills a million people, roughly 20,000 of them in the United States. These deaths could be prevented. Hepatitis B vaccine conveys 95 percent immunity, and new therapies for hepatitis C cure the vast majority of patients. A report from the National Academies of Sciences, Engineering, and Medicine, released in April, 2016 concluded that both hepatitis B and C could be rare diseases in the United States, and a report from the World Health Organization has targeted elimination of chronic viral hepatitis for most of the world by 2030. Yet many remain in the US with screening, diagnosing and treating both hepatitis B and C. Those that bear a direct relationship to public policy include training physicians to manage hepatitis B and increasing access to treatment and raising awareness of chronic hepatitis C.
The lack of awareness about the prevalence of chronic viral hepatitis in the United States and about the proper methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C contributes to continuing transmission; missing of opportunities for prevention, including vaccination; missing of opportunities for early diagnosis and medical care; and poor health outcomes in infected people.
Conference Objectives are:
• Discuss the prevalence and incidence of acute and chronic hepatitis B and hepatitis C both in the general US population and in at-risk populations.
• Review the history, epidemiology, demographics, natural history, histology, immunology and pathophysiology of the viral infection.
• Discuss state-of-the-art diagnostic and treatment guidelines for both hepatitis B and C.
• Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with HBV and/or HCV.
• Evaluate the multidisciplinary team approach to care for patients with hepatitis B and C.
• Establish a local network of practitioners for information sharing, referrals, etc.
• Improve the health of patients infected with the HBV and/or HCV virus.
Speakers: Paul Pockros, MD, Catherine Frenette, MD, Yuki Rosenkoetter, PAC, MPAS
Time: 7:30 am - 5:00 pm
Conference Description:
This Update will contribute towards increasing the number of healthcare practitioners educated on the prevalence of chronic viral hepatitis, as well as those properly preventing, diagnosing, treating, and/or referring patients with chronic illness; therefore contributing towards prevention of new cases and improved management of already infected patients.
Viral hepatitis is the seventh leading cause of death in the world, killing more people than traffic injuries, HIV and AIDS, or diabetes. Every year chronic viral hepatitis, of which hepatitis B and C are the most common forms, kills a million people, roughly 20,000 of them in the United States. These deaths could be prevented. Hepatitis B vaccine conveys 95 percent immunity, and new therapies for hepatitis C cure the vast majority of patients. A report from the National Academies of Sciences, Engineering, and Medicine, released in April, 2016 concluded that both hepatitis B and C could be rare diseases in the United States, and a report from the World Health Organization has targeted elimination of chronic viral hepatitis for most of the world by 2030. Yet many remain in the US with screening, diagnosing and treating both hepatitis B and C. Those that bear a direct relationship to public policy include training physicians to manage hepatitis B and increasing access to treatment and raising awareness of chronic hepatitis C.
The lack of awareness about the prevalence of chronic viral hepatitis in the United States and about the proper methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C contributes to continuing transmission; missing of opportunities for prevention, including vaccination; missing of opportunities for early diagnosis and medical care; and poor health outcomes in infected people.
Conference Objectives are:
• Discuss the prevalence and incidence of acute and chronic hepatitis B and hepatitis C both in the general US population and in at-risk populations.
• Review the history, epidemiology, demographics, natural history, histology, immunology and pathophysiology of the viral infection.
• Discuss state-of-the-art diagnostic and treatment guidelines for both hepatitis B and C.
• Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with HBV and/or HCV.
• Evaluate the multidisciplinary team approach to care for patients with hepatitis B and C.
• Establish a local network of practitioners for information sharing, referrals, etc.
• Improve the health of patients infected with the HBV and/or HCV virus.
Speakers: Paul Pockros, MD, Catherine Frenette, MD, Yuki Rosenkoetter, PAC, MPAS
Time: 7:30 am - 5:00 pm
KEY DATES
28 Jul, 2018
Event Start Date
28 Jul, 2018
Event End Date
SPECIALITIES
Infectious DiseaseGastroenterologySUGGESTED HOTELS
CONFERENCE VENUE
San Diego Marriott La JollaRELATED CONFERENCES & LIVE WEBINARS
Quick Links